Amarin Corp

AMRN

Market cap $406M

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian partner HLS Therapeutics, a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease (CVD), announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress (CCC), taking place in Quebec City, Quebec, Canada from October 23 to 26, 2025. These presentations reflect the continued commitment of Amarin and HLS to advancing the broader therapeutic potential of Icosapent Ethyl (IPE) and Eicosapentaenoic Acid (EPA), further highlighting their dedication to improving cardiovascular care for appropriate patients.

Amarin (AMRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Amarin (AMRN) is transforming Vascepa from a declining U.S. business into a global cardiovascular growth story, driven by disciplined expense control and strategic partnerships. AMRN's European and Rest-of-World expansion, highlighted by the Recordati deal, is offsetting U.S. revenue declines and positioning the company for asset-light, high-margin growth. Restructuring is expected to yield $70M+ in annual cost savings, with cash flow breakeven likely by late 2026 and a strong, debt-free balance sheet supporting the transition.

-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three sub-analyses from the REDUCE-IT® trial describing the impact of VASCEPA®/VAZKEPA® (icosapent ethyl - IPE) administration on cardiovascular disease (CVD) risk associated with Cardiovascular-Kidney-Metabolic (CKM) syndrome, major adverse cardiovascular events (MACE) stratified by baseline apolipoprotein B (ApoB) and fasting triglyceride rich lipoprotein cholesterol (TRL-C) levels, and on hospitalizations. All three post hoc analyses showed significant reductions in cardiovascular risk and outcomes in the populations studied. The data was presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain.

DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new data will further illuminate the multifaceted cardioprotective effects of icosapent ethyl (IPE).

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.